ProtEx technology for the generation of novel therapeutic cancer vaccines
about
4-1BB ligand as an effective multifunctional immunomodulator and antigen delivery vehicle for the development of therapeutic cancer vaccinesCD4+ T cells play a critical role in the generation of primary and memory antitumor immune responses elicited by SA-4-1BBL and TAA-based vaccines in mouse tumor models.Current challenges for cancer vaccine adjuvant development.
P2860
ProtEx technology for the generation of novel therapeutic cancer vaccines
description
2009 nî lūn-bûn
@nan
2009 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
ProtEx technology for the generation of novel therapeutic cancer vaccines
@ast
ProtEx technology for the generation of novel therapeutic cancer vaccines
@en
ProtEx technology for the generation of novel therapeutic cancer vaccines
@nl
type
label
ProtEx technology for the generation of novel therapeutic cancer vaccines
@ast
ProtEx technology for the generation of novel therapeutic cancer vaccines
@en
ProtEx technology for the generation of novel therapeutic cancer vaccines
@nl
prefLabel
ProtEx technology for the generation of novel therapeutic cancer vaccines
@ast
ProtEx technology for the generation of novel therapeutic cancer vaccines
@en
ProtEx technology for the generation of novel therapeutic cancer vaccines
@nl
P2093
P2860
P1476
ProtEx technology for the generation of novel therapeutic cancer vaccines
@en
P2093
Abhishek Srivastava
Esma S Yolcu
Haval Shirwan
Rajesh K Sharma
Rich-Henry Schabowsky
P2860
P304
P356
10.1016/J.YEXMP.2009.01.010
P577
2009-01-31T00:00:00Z